Avience Biomedicals Limited reported revenue of ₹16 crore for the quarter ended March 2026 (Q4 FY26).
Net profit stood at ₹3 crore. Earnings per share (EPS) came in at ₹7.92.
Operating profit stood at ₹6 crore — an operating margin (OPM) of 34.4%.
| Metric | Mar 2026 | YoY % | QoQ % |
|---|---|---|---|
| Sales | 16 | — | — |
| Operating Profit | 6 | — | — |
| Other Income | 0 | — | — |
| Interest | 0 | — | — |
| Depreciation | 1 | — | — |
| Profit Before Tax | 5 | — | — |
| Net Profit | 3 | — | — |
| EPS | 7.92 | — | — |
| OPM % | 34.4% | — | — |
| Metric | Mar 2026 | % Chg |
|---|---|---|
| Equity Capital | 4 | — |
| Reserves | 23 | — |
| Borrowings | 19 | — |
| Other Liabilities | 12 | — |
| Total Liabilities | 58 | — |
| Fixed Assets | 11 | — |
| CWIP | 13 | — |
| Investments | 6 | — |
| Other Assets | 28 | — |
| Total Assets | 58 | — |
| Metric | Mar 2026 | % Chg |
|---|---|---|
| Cash from Operating Activity | 6 | — |
| Cash from Investing Activity | -13 | — |
| Cash from Financing Activity | 5 | — |
| Net Cash Flow | -2 | — |
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
One tap. A short notification when there's something new — no email needed.
